Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07064759 · ClinicalTrials.gov registry record · Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by 4D Molecular Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
480
Enrollment target
20
Study locations

NCT07064759 is a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD) that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 480 participants, above the 155-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (210% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07064759, a Phase 3 study of Neovascular Age-related Macular Degeneration (nAMD), is actively recruiting participants, sponsored by 4D Molecular Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
480 participants
Enrollment target
20
Study locations

Study Summary

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Conditions Studied

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • BIOLOGICAL 4D-150 IVT (3E10 vg/eye)
  • BIOLOGICAL EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Study Locations (20)

California

  • Retinal Diagnostic Center - Campbell
  • Retina Consultants of Orange County - Fullerton
  • West Coast Retina Medical Group - San Francisco

Maryland

  • The Retina Care Center - Baltimore
  • Cumberland Valley Retina Consultants - Hagerstown
  • Mid Atlantic Retina Specialist - Hagerstown

Arizona

  • Barnet Dulaney Perkins Eye Center - Sun City
  • Retina Associates - Tucson

Florida

  • ClearVista Clinical Research - Hudson
  • Retina Vitreous Associates of Florida - Tampa

New York

  • New York Presbyterian Hospital - Columbia University Medical Center - New York
  • Vitreoretinal Consultants of NY - Westbury

South Carolina

  • Charleston Neuroscience Institute, LLC - Bluffton
  • Carolina Eyecare - Mt. Pleasant

Colorado

  • Southwest Retina Consultants - Durango

Georgia

  • Thomas Eye Group - Sandy Springs

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2025-07-22
Est. Completion 2029-02
Phase Phase 3

Sponsor

4D Molecular Therapeutics

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07064759

The ClinicalTrials.gov registry entry for NCT07064759 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 155-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (210% higher). The listed sponsor is 4D Molecular Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT (3E10 vg/eye) is the first listed.

NCT07064759 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Maryland, Arizona.

Frequently Asked Questions

What is clinical trial NCT07064759 about?

NCT07064759 is a clinical study titled "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration". A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

What is the current status of trial NCT07064759?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-07-22. Estimated completion is 2029-02.

What conditions does trial NCT07064759 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).

What interventions are being tested in trial NCT07064759?

The interventions under investigation include: 4D-150 IVT (3E10 vg/eye) (BIOLOGICAL), EYLEA® (aflibercept) Injection 2 mg (0.05mL) (BIOLOGICAL).

Who is sponsoring clinical trial NCT07064759?

This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07064759 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration (nAMD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neovascular Age-related Macular Degeneration (nAMD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.